Polycythemia Causes Artifactual, Not True Hypoglycemia
Polycythemia does not cause true hypoglycemia—it causes artifactual (false) hypoglycemia due to excessive in vitro glucose consumption by elevated white blood cells and red blood cells after blood collection and before laboratory processing. This is a critical distinction because patients remain asymptomatic despite reported low glucose values, and unnecessary workup can be avoided 1.
Mechanism of Artifactual Hypoglycemia
The phenomenon occurs through a straightforward process:
Excessive cellular glucose consumption: When blood samples sit in collection tubes, the markedly elevated white blood cells (and to a lesser extent, red blood cells) continue metabolizing glucose before the serum is separated from cellular elements 1, 2
Time-dependent artifact: This is particularly problematic when blood samples are collected in tubes without glycolysis inhibitors and when separation of plasma/serum from formed elements is delayed 3
Leukocytosis threshold: While originally described in leukemia, this artifact occurs with extreme leukocytosis regardless of underlying disease—in polycythemia vera, WBC counts between 55,000-86,000/mm³ have been documented to cause glucose values as low as 8 mg/dL despite complete absence of hypoglycemic symptoms 1
Clinical Recognition
The key diagnostic clue is asymptomatic "hypoglycemia" in a patient with documented polycythemia or extreme leukocytosis:
- Patient lacks Whipple's triad (symptoms of hypoglycemia, low plasma glucose, and resolution with glucose administration) 3
- No neuroglycopenic symptoms (confusion, seizures, altered consciousness) despite reported glucose <55 mg/dL
- No neurogenic symptoms (palpitations, tremor, sweating) that typically occur at glucose ~55 mg/dL 3
Diagnostic Approach
Immediately suspect pseudohypoglycemia when:
- Low glucose is reported in a patient with polycythemia vera or marked leukocytosis
- Patient is completely asymptomatic
- Clinical context doesn't support true hypoglycemia
Confirm the artifact by:
- Collecting blood in tubes containing fluoride (glycolysis inhibitor) and processing immediately
- Comparing point-of-care glucose (measured immediately) with delayed laboratory values
- The discrepancy confirms in vitro glucose consumption 1
Common Pitfall
The major clinical error is pursuing extensive hypoglycemia workup (72-hour fasts, insulin/C-peptide measurements, imaging for insulinoma) in an asymptomatic patient with polycythemia 3. This wastes resources and exposes patients to unnecessary testing when simply recognizing the artifact and using proper collection techniques resolves the issue 1.
Special Consideration: Neonatal Polycythemia
In neonates, the relationship differs—neonatal polycythemia and hypoglycemia may coexist but are not causally related 4. Both conditions share common risk factors (maternal diabetes, perinatal asphyxia, intrauterine growth restriction) rather than one causing the other 5, 6. When hypoglycemia occurs in polycythemic neonates, it reflects the shared underlying pathophysiology (fetal hyperinsulinism, hypoxemia) rather than the polycythemia itself causing glucose derangement 5.
HbA1c Consideration
A related but distinct issue: polycythemia affects HbA1c interpretation in diabetic patients. Elevated red blood cell counts cause underestimation of glycemic control because HbA1c reflects average glucose over RBC lifespan, and increased RBC mass dilutes the glycated hemoglobin percentage 7, 8. This is a measurement artifact affecting diabetes monitoring, not hypoglycemia per se.